ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Flavopiridol Plus Cisplatin Tested In Phase II Trial

October 26, 2007

In Brief: alberts elected To Second Term as NAS President

February 19, 1999

In Brief: FDA’s Burlington Moves to Wyeth-Ayerst; NAS Award to Beckman; Genetics Online

February 5, 1999

FDA Advisors Oppose Group’s Tamoxifen Trial, But Okay The Idea

July 6, 1990

In Brief: All 77 New NCI Positions Go to Carcinogenesis Programs; “Not Wisest Way To Use Them” – Newell

February 4, 1977

University of Pittsburgh honors breast cancer surgeon and clinical trialist Bernard Fisher with lecture and portrait.

May 13, 2005